Search company, investor...
CrystalGenomics company logo

CrystalGenomics

crystalgenomics.com

Founded Year

2000

Stage

PIPE | IPO

Market Cap

244.35B

About CrystalGenomics

CrystalGenomics (KOSDAQ: 083790) is a biopharmaceutical company dedicated to the discovery and development of drug candidates in the areas of cancer, CNS, inflammation, and infectious diseases.

Headquarters Location

700, Daewangpangyo-ro, Bundang-gu Korea Bio Park, Tower A, 5F

Seongnam, 13488,

South Korea

Missing: CrystalGenomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CrystalGenomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

CrystalGenomics Patents

CrystalGenomics has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Prodrugs
  • Analgesics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/14/2020

1/25/2022

Clusters of differentiation, Immune system, Prodrugs, Immunology, Transcription factors

Grant

Application Date

2/14/2020

Grant Date

1/25/2022

Title

Related Topics

Clusters of differentiation, Immune system, Prodrugs, Immunology, Transcription factors

Status

Grant

Latest CrystalGenomics News

Enoyl-ACP Reductase Inhibitors Pipeline Guide 2021, Featuring Debiopharm, CrystalGenomics and Nobelex Biotech - ResearchAndMarkets.com

Dec 21, 2021

How many companies are developing Enoyl-ACP reductase inhibitors drugs? How many Enoyl-ACP reductase inhibitors drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Enoyl-ACP reductase inhibitors? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Enoyl-ACP reductase inhibitors therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Enoyl-ACP reductase inhibitors and their status? What are the key designations that have been granted to the emerging drugs? Key Players

CrystalGenomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CrystalGenomics Rank

CrystalGenomics Frequently Asked Questions (FAQ)

  • When was CrystalGenomics founded?

    CrystalGenomics was founded in 2000.

  • Where is CrystalGenomics's headquarters?

    CrystalGenomics's headquarters is located at 700, Daewangpangyo-ro, Bundang-gu, Seongnam.

  • What is CrystalGenomics's latest funding round?

    CrystalGenomics's latest funding round is PIPE.

  • Who are the investors of CrystalGenomics?

    Investors of CrystalGenomics include VAXIMM.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.